Sign inJoin free

Watch / Small Cap

Chimeric Therapeutics' global first

16 Dec 20246:12

Chimeric Therapeutics' global first

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

Rebecca McQualter of Chimeric Therapeutics shares updates on their cancer cell therapies.

She says the company are pioneering the use of 'off the shelf' stem core NK cells to treat acute myeloid leukaemia at MD Anderson Cancer Center. This marks a global first in cell therapy.

Rebecca explains that Chimeric is expanding its trials to Australia while also maintaining US operations. She explains that funding is solid with a $5M placement and a $4.1M R&D tax credit.

Chimeric is on track for Phase 2 trials next year, and Rebecca says several more announcements are ahead.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy